Dallas Salazar • Thu, Nov. 20
Be smarter and faster with PRO Alerts on IMS
From other sites
at CNBC.com (Jun 19, 2014)
at CNBC.com (Jun 19, 2014)
at CNBC.com (May 22, 2014)
at MarketWatch.com (Apr 9, 2014)
at CNBC.com (Apr 7, 2014)
There are 3 articles on this stock available only to PRO subscribers.
- Sadly, I have to sell away my IMS position, taking home only half the return that IMS offered just weeks ago.
- IMS exposure to USD strength and its inability to hedge against this in size will allow margin contraction and income statement pressure to continue into the mid-term.
- I think IMS is a long-term core position, but I cant own shares into what is highly visible bottom line pressure from FX.
IMS Has Deleveraged While Growing Revenues And Executing Accretive Acquisitions
- IMS has one heck of a story to tell and its shares have reflected that up 19% since its IPO in mid-April.
- IMS should complete an accretive acquisition in early 2015 that would have contributed 10% to FY13's Adjusted EBITDA and 340 basis points to Adjusted EBITDA margins.
- IMS has completed 22 acquisitions since 2010 and has managed to reduce its gross leverage ratio from 6X to 4.6X in the process.
- IMS Health makes a stellar deal by acquiring Cegedim.
- A sizable valuation discount and huge synergies improve appeal and send shares higher.
- Yet the overall valuation is high amidst a leveraged balance sheet, low earnings and a demanding valuation.
With The IPO Behind It IMS Looks To Get Back To The Regularly Scheduled Program
- IMS had a highly unusual quarter that is reflected in a highly unusual set of financials.
- IMS has a very profitable underlying business, one that should be able to resume course with the IPO out of the way.
- IMS' recent debt payoffs and restructurings as a result of the IPO addressed the largest concern facing the company on an immediate-term basis.
- Great Quality Business With A Strong History And Solid Growth Prospects.
- Unfortunately A Leveraged Buyout Leaves IMS Fairly Highly Leveraged.
- Sophisticated Sellers Leave Little On The Table.
IMS Health Holdings Has Core Position Potential And Should Be On Your Watchlist
- IMS IPO has allows new money to take advantage of 60 years worth of infrastructure and brand building.
- IMS provides a predictable financial picture that should improve Q/Q and Y/Y as they increase average and net billings.
- IMS recent majority ownership change will provide ongoing material benefits at no cost to the company.
- IMS is a global information and technology services firm, providing healthcare information to various healthcare organizations.
- IMS plans to raise $1.27 billion in its upcoming IPO, offering 65.0 million shares, including 20% insider shares, at an expected price range of $18-$21 per share.
- We rate IMS a buy—being an industry leader, with an impressive leadership team.
Thu, Nov. 20, 7:41 AM
- According to IMS Health (NYSE:IMS) global drug spending will top $1T this year led by Gilead's (NASDAQ:GILD) Sovaldi (sofosbuvir) for hep C and new cancer drugs. The projected spend of $1.06T represents a 7% increase from last year.
- By 2018, drug spending is projected to rise to $1.3T. Hepatitis C and cancer meds will add ~$100B each, while diabetes care will contribute $78B. Leading the charge in cancer will be Roche's (OTCQX:RHHBY) Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine), Pharmacyclics' (NASDAQ:PCYC) Imbruvica (ibrutinib) and Amgen's (NASDAQ:AMGN) Kyprolis (carfilzomib).
- The ever-increasing tab for meds will be controversial because payers' budgets are being stressed while drug developers defend their prices citing high development costs.
- There is already some push back in cancer. Britain's National Institute for Health and Care Excellence (NICE), which sets guidelines for the National Health Service on costs, procedures and technologies, is balking at approving Roche's Gazyvaro (obinutuzumab) and Kadcyla citing their high cost relative to additional benefits over existing therapies.
- Previously: Roche's Gazyvaro not NICE in the UK
- ETFs: IBB, BIB, IRY, BIS, IXJ, DRGS
Fri, Oct. 24, 12:59 PM
- IMS Health Holdings (IMS -6.4%) Q3 results: Revenues: $656M (+3.6%); Information: $382M (+0.3%); Technology Sevices: $274M (+8.7%); Operating Expenses: $311M (+6.1%); Net Income: $47M (+335.0%); EPS: $0.14 (+300.0%); Quick Assets: $354.0M (-51.2%); CF Ops: $191M.
- 2014 Guidance: Revenue growth of 5.5 - 5.7% from 5 - 6%; Adjusted EBITDA growth: 9.0 - 9.8% from 7.5 - 9%; Adjusted Net Income growth: 20 - 21% from 15 - 20%.
Fri, Oct. 24, 7:04 AM
Thu, Oct. 23, 5:30 PM
Fri, Oct. 10, 4:21 PM
Thu, Jul. 24, 8:37 AM
- IMS Health Holdings (NYSE:IMS) Q2 results: Revenue: $662M (+6.1%), Information: $386M (+1.8%), Technology Services: $276M (+12.7%); Cost of Services: $314M (+11.7%); SG&A Expense: $247M (+70.3%); Operating Income/Loss: ($39M) (-140.2%); Net Income/Loss: ($220M) (-999%); EPS: ($0.67) (-999%); Quick Assets: $266M (-63.5%); CF Ops: ($126M) (-200.0%).
- 2014 Guidance: Revenue growth: 5 - 6%; adjusted EBITDA growth: 7.5 - 9%; adjusted net income growth: 15 - 20%.
Thu, Jul. 24, 7:21 AM
Wed, Jul. 23, 5:30 PM
- AAL, ABC, ALK, ALXN, ARG, ASPS, BBW, BC, BCC, BHE, BKU, BMS, BMY, BPOP, BSX, CAB, CAM, CAT, CCE, CELG, CLF, CLFD, CLI, CMS, COG, CRI, CRY, CSH, CWEI, DAN, DFT, DGX, DHI, DLX, DNKN, DO, DPS, DST, ECA, EQM, EQT, F, FAF, FLIR, GM, GNTX, GPI, GPK, GRUB, HOT, HSY, IMAX, IMS, IQNT, ISSI, IVC, JAH, JBLU, KEM, KKR, LAZ, LLY, LTM, LUV, MHO, MMM, MTH, MTRN, NBL, NDAQ, NOK, NUE, NWE, O, ORI, OSTK, PCP, PDS, PENN, PHM, PNK, POT, PRLB, PTEN, QSII, RCI, RCL, RDWR, RS, RTIX, RTN, SCHL, SFE, SIAL, SQNS, SUI, SVU, SXC, TDY, TROW, TWI, UA, UAL, UFS, UNP, USG, VAC, VDSI, VIVO, WAB, WCC, WIT, WYN, ZMH
Tue, Jun. 24, 6:00 PM
- IMS Health (IMS) is buying Cegedim's (CGMJF) information solutions and CRM businesses for €385M ($520M) in cash. The deal is expected to close in early 2015.
- The Cegedim businesses had 2013 revenue of $573M, and adjusted EBITDA of $86. The purchase is expected to be immediately accretive to adjusted EPS.
- IMS +5.1% AH.
Tue, Jun. 24, 5:38 PM
Mon, Jun. 9, 5:51 PM
Thu, May. 8, 9:18 AM| Comment!
Thu, May. 1, 8:59 AM
Fri, Apr. 4, 11:39 AM
- Healthcare research firm IMS Health Holdings (IMS) zooms up in its first day of trading on heavy volume.
- The firm, formed in 1954, boasts the largest healthcare database in the world with 10 petabytes of data from 100,000 data suppliers and 780,000 data feeds. It contains 400M anonymous longitudinal patient records and tracks 85% of the world's prescriptions by dollar volume.
- The company processes data from 45B healthcare transactions per year.
- 2013 sales were $1.9B, operating income $276M and CF Ops $322M.
Fri, Apr. 4, 10:10 AM
Fri, Apr. 4, 2:48 AM
- IMS Health Holdings (IMS) is due to start trading on the NYSE today after the healthcare information company priced its IPO at $20 a share, giving it a market cap of $6.64B.
- The offering raised $1.3B, with IMS selling 52M shares and its owners 13M. There's also an over-allotment option of 9.75M shares.
- The share price was slightly above the midpoint of the IPO's expected price range of $18-$21 a share.
- IMS's flotation comes four years after TPG, Canada Pension Plan Investment Board and Leonard Green took the company private in 2010 for $5.2B, including debt.
- ETF: IPO
IMS vs. ETF Alternatives
IMS Health Holdings Inc is an information and technology services company. It offers various information offerings developed to meet its clients' needs by using data secured from network of suppliers. It provides service to healthcare organizations.
Other News & PR